The Effect of mRNA-Based COVID-19 Vaccination on Anti-Programmed Cell Death Protein 1 Blockade for Nasopharyngeal Cancer May Differ From a Virus-Inactivated Vaccine.
作者信息
Hayashi Takuma, Konishi Ikuo
机构信息
Cancer Medicine, National Hospital Organization Kyoto Medical Centre, Kyoto, Japan.
Department of Medical R&D Promotion Project, The Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
出版信息
World J Oncol. 2023 Aug;14(4):316-320. doi: 10.14740/wjon1620. Epub 2023 Jul 12.
Abstract
摘要
相似文献
1
The Effect of mRNA-Based COVID-19 Vaccination on Anti-Programmed Cell Death Protein 1 Blockade for Nasopharyngeal Cancer May Differ From a Virus-Inactivated Vaccine.基于信使核糖核酸的新冠疫苗接种对鼻咽癌程序性细胞死亡蛋白1阻断治疗的影响可能与灭活病毒疫苗不同。
World J Oncol. 2023 Aug;14(4):316-320. doi: 10.14740/wjon1620. Epub 2023 Jul 12.
2
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?mRNA 疫苗与灭活病毒 COVID-19 疫苗在多发性硬化症中的应用：体液免疫应答和保护作用——这有关系吗？
Mult Scler Relat Disord. 2023 Jul;75:104761. doi: 10.1016/j.msard.2023.104761. Epub 2023 May 10.
3
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.针对多发性硬化症患者的 SARS-CoV-2 灭活疫苗和 mRNA 疫苗的安全性和体液免疫应答率。
Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.
4
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine.在感染 HIV 的人群中，接种严重急性呼吸综合征冠状病毒 2 疫苗后的替代中和反应：灭活疫苗和 mRNA 疫苗之间的比较。
AIDS. 2022 Jul 15;36(9):1255-1264. doi: 10.1097/QAD.0000000000003237. Epub 2022 Apr 23.
5
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
6
COVID-19 After Vaccination in Lung Transplant Recipients: Real-Life Data.肺移植受者接种疫苗后感染新冠病毒：真实数据
Exp Clin Transplant. 2023 Mar;21(3):265-271. doi: 10.6002/ect.2022.0088. Epub 2022 Jul 22.
7
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].《中国季节性流感疫苗接种技术指南（2022—2023年）》
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840.
8
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.癌症治疗患者接种 COVID-19 疫苗后的抗体和 T 细胞反应。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004766.
9
Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2-inactivated vaccine.突破性感染引发了由 SARS-CoV-2 灭活疫苗建立的鼻咽部固有免疫反应。
Front Immunol. 2023 Jun 29;14:1181121. doi: 10.3389/fimmu.2023.1181121. eCollection 2023.
10
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.评价由科兴中维生产的新型冠状病毒（灭活）疫苗对医护人员的有效性和安全性的双盲、随机、安慰剂对照 III 期临床试验 - PROFISCOV：一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.
引用本文的文献
1
Vaccines for preventing infections in adults with solid tumours.用于预防实体瘤成年患者感染的疫苗。
Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD015551. doi: 10.1002/14651858.CD015551.pub2.
2
Implications of HPV infectivity in early diagnosis and treatment of advanced/recurrent malignancies.人乳头瘤病毒感染性在晚期/复发性恶性肿瘤早期诊断和治疗中的意义
BJC Rep. 2024 Jan 29;2(1):7. doi: 10.1038/s44276-024-00036-y.
本文引用的文献
1
Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy.接种新冠疫苗的鼻咽癌患者对抗PD-1阻断联合化疗的反应可能得到改善。
Ann Oncol. 2023 Jan;34(1):121-123. doi: 10.1016/j.annonc.2022.10.002. Epub 2022 Oct 7.
2
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一种灭活严重急性呼吸综合征冠状病毒2疫苗（科兴新冠疫苗）在60岁及以上健康成年人中的安全性、耐受性和免疫原性：一项随机、双盲、安慰剂对照的1/2期临床试验
Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3.
3
Nivolumab for Squamous-Cell Cancer of Head and Neck.
N Engl J Med. 2017 Feb 9;376(6):596. doi: 10.1056/NEJMc1615565.
4
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
Zotero 插件